Cardiome Pharma Corp. to Present at Bloom Burton & Co. Healthcare Investor Conference
NASDAQ: CRME TSX: COM
VANCOUVER, May 10, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced President & CEO, Dr. William Hunter, is presenting an update of the Company's progress at the Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade in Toronto on May 22, 2013.
Dr. Hunter's presentation will include an update of the Company's business including the recent launch of BRINAVESSTM in Europe by the Cardiome sales force.
Cardiome's corporate presentation will be available for viewing following Dr. Hunter's presentation on May 22, 2013 from the Company's website at www.cardiome.com.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one
marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the
rapid conversion of recent onset atrial fibrillation to sinus rhythm in
adults.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
"believe", "may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Forward- looking
statements may involve, but are not limited to, comments with respect
to our objectives and priorities for the remainder of 2013 and beyond,
our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research and development and product and drug development. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others,
the following: general economic and business conditions in the United
States, Canada, Europe, and the other regions in which we operate;
market demand; technological changes that could impact our existing
products or our ability to develop and commercialize future products;
competition; existing governmental legislation and regulations and
changes in, or the failure to comply with, governmental legislation and
regulations; availability of financial reimbursement coverage from
governmental and third-party payers for products and related
treatments; adverse results or unexpected delays in pre-clinical and
clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products; decisions, and the
timing of decisions, made by health regulatory agencies regarding
approval of our technology and products; the requirement for
substantial funding to expand commercialization activities; and any
other factors that may affect our performance. In addition, our
business is subject to certain operating risks that may cause any
results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These
operating risks include: our ability to attract and retain qualified
personnel; our ability to successfully complete pre-clinical and
clinical development of our products; changes in our business strategy
or development plans; intellectual property matters, including the
unenforceability or loss of patent protection resulting from
third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture,
market and sell our products; the availability of capital to finance
our activities; and any other factors described in detail in our
filings with the Securities and Exchange Commission available at
www.sec.gov and the Canadian securities regulatory authorities at
www.sedar.com. Given these risks, uncertainties and factors, you are
cautioned not to place undue reliance on such forward-looking
statements and information, which are qualified in their entirety by
this cautionary statement. All forward-looking statements and
information made herein are based on our current expectations and we
undertake no obligation to revise or update such forward-looking
statements and information to reflect subsequent events or
circumstances, except as required by law.
SOURCE Cardiome Pharma Corp.
Help employers find you! Check out all the jobs and post your resume.